65,437 trials
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason — 18.4; 20.1; 24.6 percentage of participants — p=0.017
Relapsing-Remitting Multiple Sclerosis
Primary: Number of Participants With Anti-DAC HYP Binding Antibodies (ADAbs): Electrochemiluminescent (ECL) Anti-Drug Antibody (ADA) Assay — 78; 35; 92; 21 participants
Differentiated Thyroid Cancer
Primary: Progression-Free Survival (PFS) — 10.0; 5.7 months — p=0.080
Breast Cancer
Primary: Number of Patients Who Completed All Planned Therapy — 45 participants
Food Hypersensitivity
Primary: Percentage of Subjects Who Develop Desensitization — 81.25 percentage of participants
Plaque Psoriasis
Primary: The Number of Subjects With HPA Axis Suppression — 0; 5; 5 Participants
Diabetes · Metabolic Syndrome · Insulin Resistance
Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale
Multiple Myeloma
Primary: To Evaluate the Best Overall Response Rate (ORR) — 1; 8; 9; 3 Participants
Osteoporosis Postmenopausal
Primary: Percent Change From Baseline to Week 52 in Lumbar Spine Bone Mineral Density (BMD) at Lumbar Vertebrae 1 to 4 (L1-L4) — 0.55; 4.09; 5.67; 5.94 percent change — p=<0.001
Multiple Sclerosis
Primary: Modified Fatigue Impact Scale — 46.1; 46.7 units on a scale — p=.64
Dysphagia · Dysplasia · Esophageal Adenocarcinoma
Primary: Sensitivity of Sponge Cytology Using FISH — 13.3 percentage of cases among positive tests
Psoriasis
Primary: Percentage of Participants With Treatment Success According to the Investigator's Global Assessment (IGA) — 21.50; 7.4 percentage of subjects
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
COPD
Primary: Change From Baseline to Day 7 in Trough FEV1 (Forced Expiratory Volume in 1 Second) — 91.2; 92.8; 113.1; 151.9 FEV1 (mL)
Children
Primary: Number of Adverse Events — 61; 35; 52; 38 Number of AE reported